Transforming the
future of colorectal
cancer therapy
Akamis Bio is working to advance the standard of care in colorectal cancer by developing oncolytic immunotherapies which aim to provide new hope to people living with this devastating disease.
Commitment to Patients
We are on a mission to transform the treatment of colorectal cancer with oncolytic immunotherapies capable of simulating the body’s own defenses to recognize, attack and clear a patient’s tumor.
There is a critical unmet need for new therapies to treat colorectal cancer – the second leading cause of cancer deaths globally and whose incidence is rising at an alarming rate in adults under 50 years of age.
Clinical Trial: Phase 1b
Learn about our lead clinical program (NG-350A) which is being studied in mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC) patients in the currently enrolling FORTRESS clinical trial.
Our Pipeline
Our pipeline is focused on one goal – to bring meaningful new therapies to
people living with colorectal cancer.
Our Technology
T-SIGn® therapeutics are systemically administered, tumor-specific oncolytic immunotherapies that directly attack tumor tissue while delivering immune-modulating payloads directly to the tumor microenvironment.